

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

LNCaP clone FGC

RRID:CVCL_1379

Type: Cell Line

Proper Citation

RRID:CVCL_1379

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1379

Proper Citation: RRID:CVCL_1379

Description: Cell line LNCaP clone FGC is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:2734981](#), [PMID:8104329](#), [PMID:10092147](#), [PMID:11172901](#), [PMID:12725112](#), [PMID:15389782](#), [PMID:15833837](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23117885](#), [PMID:23325432](#), [PMID:27397505](#), [PMID:28145883](#), [PMID:30305041](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP clone FGC

Synonyms: LNCaP-Clone-FGC, LNCaP.FGC, LNCaP-FGC, LNCaP FGC, LNCAPCLONEFGC, LNCaP-ATCC, LNCaP Fast Growing Colony

Cross References: BTO:BTO_0006095, CLO:CLO_0007366, CLO:CLO_0007367, CLO:CLO_0051537, EFO:EFO_0005726, CLDB:cl3245, CLDB:cl4960, CLDB:cl5222, 4DN:4DNSR4OQOB67, Abcam:ab275470, AddexBio:C0019003/4953, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1740,

BCRC:60088, BCRJ:0149, BioGRID_ORCS_Cell_line:930, BioSample:SAMN03471417, BioSample:SAMN03472018, BioSample:SAMN05292444, BioSample:SAMN10988285, cancercellines:CVCL_1379, CCRID:3101HUMSCSP5021, CCRID:3101HUMTCHu173, Cell_Model_Passport:SIDM00683, ChEMBL-Cells:ChEMBL3308342, ChEMBL-Targets:ChEMBL2366172, CLS:305220, Cosmic:688117, Cosmic:907788, Cosmic-CLP:907788, DepMap:ACH-000977, ECACC:89110211, EGA:EGAS00001000978, ENCODE:ENCBS089RMT, ENCODE:ENCBS184PDN, ENCODE:ENCBS235TSM, ENCODE:ENCBS260TRO, ENCODE:ENCBS386ENC, ENCODE:ENCBS387ENC, ENCODE:ENCBS418ENC, ENCODE:ENCBS421PUJ, ENCODE:ENCBS422ENC, ENCODE:ENCBS535BWO, ENCODE:ENCBS668DEO, ENCODE:ENCBS680JNS, ENCODE:ENCBS687TQL, ENCODE:ENCBS849SWQ, ENCODE:ENCBS851ZZS, ENCODE:ENCBS918PKZ, GDSC:907788, GEO:GSM383954, GEO:GSM383955, GEO:GSM383956, GEO:GSM651578, GEO:GSM651579, GEO:GSM827569, GEO:GSM887271, GEO:GSM888346, GEO:GSM1633299, GEO:GSM1633300, GEO:GSM1633301, GEO:GSM1633323, GEO:GSM1633324, GEO:GSM1633325, GEO:GSM1670051, GEO:GSM3407130, GEO:GSM3407131, GEO:GSM3407132, GEO:GSM3407133, GEO:GSM3407134, GEO:GSM3407135, IARC_TP53:27698, ICLC:HTL99011, IZSLER:BS TCL 148, KCB:KCB 200732YJ, KCLB:21740, LiGeA:CCL_749, PharmacDB:LNCaPCloneFGC_851_2019, PRIDE:PXD030304, Progenetix:CVCL_1379, PubChem_Cell_line:CVCL_1379, RCB:RCB2144, TKG:TKG 0603, Ubigen:YC-C009, Wikidata:Q54902825

ID: CVCL_1379

Hierarchy: cvcl_0395

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260905T181035+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP clone FGC.

No alerts have been found for LNCaP clone FGC.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 165 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Macke AJ, et al. (2026) Dynamic Shifts in ER-Plasma Membrane Junctions Signaling Define Pro-Metastatic N-Glycosylation and Predict Prostate Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(30), e22885.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.

Berzoti-Coelho MG, et al. (2026) PVT1 lincRNA signals an androgen-dependent transcriptional activation program of oncogenes in prostate cancer cells. *International journal of cancer*, 159(1), 144.

Rouhimoghadam M, et al. (2026) Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22. *Cell chemical biology*.

Kong X, et al. (2026) Anticancer Activity of Novel Trifluoromethylquinoline Derivatives Designed to Target the Tubulin Colchicine Binding Site. *Chemistry & biodiversity*, 23(6), e71420.

Zhang C, et al. (2026) GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. *Advanced science (Weinheim, Baden-Wuerttemberg, Germany)*, 13(26), e16411.

Rodrigues SD, et al. (2026) Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression. *bioRxiv : the preprint server for biology*.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Severson TM, et al. (2025) Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer. *Cell reports. Medicine*, 6(7), 102215.

Tamarindo GH, et al. (2025) DHA suppresses hormone-sensitive and castration-resistant prostate cancer growth by decreasing de novo lipogenesis. *Biochimica et biophysica acta. Molecular and cell biology of lipids*, 1870(5), 159634.

Khan S, et al. (2025) Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy. *International journal of molecular sciences*, 26(24).

Thomsen MT, et al. (2025) The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors. *BMC cancer*, 25(1), 535.

Kudo KI, et al. (2025) Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cells. *bioRxiv : the preprint server for biology*.

Cipolla R, et al. (2025) PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration. *iScience*, 28(12), 113931.

Zhu S, et al. (2025) Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer. *Molecular cell*, 85(14), 2673.

Xiang RR, et al. (2025) CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. *Cell reports*, 44(2), 115312.

Thisted T, et al. (2025) Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell Activation. *Cancer immunology research*, 13(12), 1956.

Chen Y, et al. (2025) ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. *iScience*, 28(10), 113520.

Sipola J, et al. (2025) Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer. *Cancer research*, 85(4), 791.

ChallaSivaKanaka S, et al. (2025) DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer. *bioRxiv : the preprint server for biology*.